Top Page
HEALWELL AI
(TSX:AIDX)
HEALWELL AI (AIDX) vs. iShares MSCI Canada ETF (EWC)
HEALWELL AI Business Overview & Revenue Model
HEALWELL AI Earnings Call Summary
HEALWELL AI Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.97M | 7.32M | 10.42M | 47.82M | 38.57M |
| Gross Profit | 17.32M | 1.26M | 3.71M | 15.01M | 64.22M |
| EBITDA | -18.42M | -16.11M | -13.94M | -11.44M | 2.11M |
| Net Income | -26.29M | -31.60M | -21.09M | -15.67M | -1.03M |
Balance Sheet | |||||
| Total Assets | 125.53M | 53.70M | 45.63M | 60.89M | 22.36M |
| Cash, Cash Equivalents and Short-Term Investments | 9.68M | 19.16M | 1.80M | 7.68M | 1.27M |
| Total Debt | 22.20M | 20.93M | 17.42M | 14.35M | 15.04M |
| Total Liabilities | 51.86M | 32.23M | 32.13M | 31.14M | 22.12M |
| Stockholders Equity | 63.89M | 12.65M | 11.78M | 28.03M | 114.00K |
Cash Flow | |||||
| Free Cash Flow | -23.93M | -10.86M | -9.49M | -9.47M | 3.99M |
| Operating Cash Flow | -22.62M | -10.80M | -8.35M | -7.10M | 4.22M |
| Investing Cash Flow | -15.37M | 1.35M | -1.17M | -8.64M | -234.00K |
| Financing Cash Flow | 28.24M | 27.20M | 3.78M | 21.99M | -4.22M |
HEALWELL AI Technical Analysis
HEALWELL AI Peers Comparison
HEALWELL AI Corporate Events
HEALWELL AI and its subsidiary Orion Health have signed a Memorandum of Understanding with Lean Business Services to explore the development and commercialization of AI-driven healthcare solutions in the Middle East and global markets. This collaboration aims to leverage HEALWELL’s AI capabilities, Orion Health’s interoperability expertise, and Lean’s market leadership in Saudi Arabia to improve population health outcomes and accelerate AI adoption in clinical workflows, aligning with Saudi Arabia’s Vision 2030 healthcare objectives.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI announced it will release its Fiscal Third Quarter 2025 financial results on November 6, 2025, followed by a conference call and webcast on November 7, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational progress, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI Inc. has filed an amended business acquisition report for its acquisition of Orion Health Holdings Limited, initially closed on April 1, 2025. The amendment updates the audit report to comply with International Standards on Auditing (ISA), replacing the previous compliance with ISA (New Zealand). This change was made following a review by the Ontario Securities Commission, ensuring the audit report aligns with ISA requirements and includes additional auditor responsibilities disclosure.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$3.80 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI recently completed a week-long series of business development and investor awareness activities in the UK, highlighting its AI-driven preventative healthcare solutions. The company engaged with prospective investors, partners, and acquisition targets, and hosted an exclusive event in London attended by healthcare leaders and financial institutions. The discussions emphasized the integration of AI into global healthcare systems, showcasing HEALWELL’s role as a key data science vendor for the UK NHS. The event reinforced the alignment between AI innovation and healthcare investment, and highlighted opportunities for HEALWELL to expand its presence in the UK market, leveraging its acquisition of Orion Health to accelerate growth.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$3.80 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI, in collaboration with Takeda Pharmaceutical, has demonstrated a groundbreaking use of its DARWEN™ AI platform to generate regulatory-grade real-world data on vedolizumab dose escalation for ulcerative colitis and Crohn’s disease. This achievement, presented at the United European Gastroenterology Week, highlights the platform’s potential to enhance patient outcomes and drive pharmaceutical advancements, further solidifying HEALWELL’s position as a leader in healthcare AI.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI has announced the global launch of AmadeusAI, an AI-enabled digital care record, following its integration with DARWEN™ AI and the acquisition of Orion Health. This launch introduces the SMARTSuite of AI tools, including SMARTSearch, SMARTSummary, and SMARTIdentify, which streamline clinical workflows, enhance patient data synthesis, and support proactive care planning. The integration aims to empower healthcare providers with advanced capabilities for analyzing clinical data, identifying at-risk patients, and improving population health management, ultimately enhancing the efficiency and effectiveness of healthcare delivery.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI’s subsidiary, Intrahealth Systems Limited, has been selected by Public Health Sudbury & Districts to implement its Profile EMR platform. This initiative aims to modernize digital infrastructure, improve efficiency, and enhance public health services across various programs, including infectious disease control, sexual health, and environmental health. The deployment of Profile is expected to strengthen community health outcomes by enabling data-driven decision-making and increasing accessibility through digital portals and telemedicine.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI Inc. reported record revenue growth of 645% in Q2-2025, reaching $40.5 million, largely driven by the acquisition of Orion Health. This acquisition has significantly bolstered HEALWELL’s healthcare software business, which saw a 1,064% year-over-year increase. The company achieved its first quarter of positive Adjusted EBITDA, marking a pivotal shift in its financial trajectory and validating its scalable AI-driven business model. HEALWELL is focusing on becoming a pure-play digital SaaS and services company, divesting its clinical research and patient services units to concentrate on AI and healthcare software innovation. The strategic move aims to enhance its market position, leveraging existing customer bases and contracts to facilitate the adoption of AI solutions in healthcare systems worldwide.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI announced it will release its Fiscal Second Quarter 2025 financial results on August 13, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.